Search

Displaying results 2441 - 2450 of 10000 in total
  1. Drug

    Atrasentan

    go.drugbank.com/drugs/DB06199
    ApprovedInvestigational

    [L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist … Atrasentan is a novel, selective endothelin A receptor antagonist (SERA).

    Categories: Endothelin A Receptor Antagonists
  2. Drug

    Pralsetinib

    go.drugbank.com/drugs/DB15822
    ApprovedInvestigational

    Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated … [A202049, A202055, L15986] Although a phase 1/2 trial of pralsetinib termed ARROW (NCT03037385) is still ongoing, pralsetinib was granted accelerated FDA approval on September 4, 2020, for the treatment

  3. Drug

    Miglustat

    go.drugbank.com/drugs/DB00419
    ApprovedInvestigational

    It has recently been approved for treatment of progressive neurological symptoms in adult and pediatric patients in the European Union, Brazil, and South Korea. … However, clinical experience with miglustat showed that therapeutic levels of the drug could not be achieved in patients without a high incidence of adverse effect.

    Synonyms: N-(n-Butyl)deoxynojirimycin, N-Butylmoranoline
  4. Drug

    Islatravir

    go.drugbank.com/drugs/DB15653
    ApprovedInvestigational

    Islatravir is a first-in-class, highly potent nucleoside reverse transcriptase translocation inhibitor (NRTTI) used in combination therapy for the treatment of HIV-1 infection. … [A275492, L56138] Chemically, it is a deoxyadenosine analogue distinguished by a 4'-ethynyl group and a 2-fluoro substitution, which collectively enhance its metabolic stability and potency.

  5. Drug

    Nabilone

    go.drugbank.com/drugs/DB00486
    ApprovedInvestigational

    If not provided in their activated form (such as through synthetic forms like Nabilone or [DB00470]), THC and CBD are obtained through conversion from their precursors, tetrahydrocannabinolic acid-A (THCA-A … Though it was approved by the FDA in 1985, the drug only began marketing in the United States in 2006. It is also approved for use in treatment of anorexia and weight loss in patients with AIDS.

  6. Drug

    Raloxifene

    go.drugbank.com/drugs/DB00481
    ApprovedInvestigational

    However, it has a negligible effect on altering the development and progression of breast cancer itself. … In addition, a clinical study consisting of postmenopausal women with documented coronary heart disease or at increased risk for coronary events showed an increased risk for fatal stroke with raloxifene

  7. Drug

    Ditiocarb zinc

    go.drugbank.com/drugs/DB14193
    Approved

    Ditiocarb zinc, also known as Diethyldithiocarbamic acid zinc salt, is a known chelator for copper and zinc. It also a dermatological sensitizer and allergen. … Sensitivity to ditiocarb zinc may be identified with a clinical patch test.

    Synonyms: Zinc N,N-diethyldithiocarbamateCategories: Compounds used in a research, industrial, or household setting
  8. Drug

    Mycophenolic acid

    go.drugbank.com/drugs/DB01024
    ApprovedInvestigational

    Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone. … Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis.

    Categories: UGT1A1 Substrates with a Narrow Therapeutic Index, UGT1A6 Substrates with a Narrow Therapeutic IndexProducts: MYCOPHENOLAT 1A 250MG HART, MYCOPHENOLAT 1A PHAR 500MG
  9. Drug

    Ranolazine

    go.drugbank.com/drugs/DB00243
    ApprovedInvestigational

    [L3580] With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.[L5440] … Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities.

  10. Drug

    Chlorine dioxide

    go.drugbank.com/drugs/DB12453
    Approved

    Chlorine Dioxide has been used in trials studying the treatment of Halitosis.

    Categories: Compounds used in a research, industrial, or household settingProducts: Skin N Clean